Literature DB >> 22007076

Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis.

Daniel G Hackam1, Mark Woodward, L Kristin Newby, Deepak L Bhatt, Mingyuan Shao, Eric E Smith, Allan Donner, Muhammad Mamdani, James D Douketis, Hisatomi Arima, John Chalmers, Stephen MacMahon, David L Tirschwell, Bruce M Psaty, Cheryl D Bushnell, Maria I Aguilar, Dan J Capampangan, David J Werring, Paola De Rango, Anand Viswanathan, Nicolas Danchin, Ching-Lan Cheng, Yea-Huei Kao Yang, B Marianne Verdel, Mei-Shu Lai, James Kennedy, Shinichiro Uchiyama, Takenori Yamaguchi, Yasuo Ikeda, Marko Mrkobrada.   

Abstract

BACKGROUND: A recent large, randomized trial suggested that statins may increase the risk of intracerebral hemorrhage. Accordingly, we systematically reviewed the association of statins with intracerebral hemorrhage in randomized and observational data. METHODS AND
RESULTS: We screened 17 electronic bibliographic databases to identify eligible studies and consulted with experts in the field. We used DerSimonian-Laird random-effects models to compute summary risk ratios with 95% confidence intervals. Randomized trials, cohort studies, and case-control studies were analyzed separately. Only adjusted risk estimates were used for pooling observational data. We included published and unpublished data from 23 randomized trials and 19 observational studies. The complete data set comprised 248 391 patients and 14 784 intracerebral hemorrhages. Statins were not associated with an increased risk of intracerebral hemorrhage in randomized trials (risk ratio, 1.10; 95% confidence interval, 0.86-1.41), cohort studies (risk ratio, 0.94; 95% confidence interval, 0.81-1.10), or case-control studies (risk ratio, 0.60; 95% confidence interval, 0.41-0.88). Substantial statistical heterogeneity was evident for the case-control studies (I(2)=66%, P=0.01), but not for the cohort studies (I(2)=0%, P=0.48) or randomized trials (I(2)=30%, P=0.09). Sensitivity analyses by study design features, patient characteristics, or magnitude of cholesterol lowering did not materially alter the results.
CONCLUSIONS: We found no evidence that statins were associated with intracerebral hemorrhage; if such a risk is present, its absolute magnitude is likely to be small and outweighed by the other cardiovascular benefits of these drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22007076     DOI: 10.1161/CIRCULATIONAHA.111.055269

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  41 in total

1.  Incident risk and progression of cerebral microbleeds in healthy adults: a multi-occasion longitudinal study.

Authors:  Ana M Daugherty; Naftali Raz
Journal:  Neurobiol Aging       Date:  2017-07-18       Impact factor: 4.673

2.  LDL Lowering After Acute Coronary Syndrome: Is Lower Better?

Authors:  Gautam Reddy; Vera Bittner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

3.  Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study.

Authors:  Kieran L Quinn; Erin M Macdonald; Muhammad M Mamdani; Christina Diong; David N Juurlink
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

4.  Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users.

Authors:  Ryan M Carnahan; Joshua J Gagne; Christian Hampp; Charles E Leonard; Sengwee Toh; Candace C Fuller; Sean Hennessy; Laura Hou; Noelle M Cocoros; Genna Panucci; Tiffany Woodworth; Austin Cosgrove; Aarthi Iyer; Elizabeth A Chrischilles
Journal:  Pharmaceut Med       Date:  2019-02

5.  Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics.

Authors:  Charles E Leonard; Colleen M Brensinger; Warren B Bilker; Stephen E Kimmel; Xu Han; Young Hee Nam; Joshua J Gagne; Margaret J Mangaali; Sean Hennessy
Journal:  Int J Cardiol       Date:  2016-11-12       Impact factor: 4.164

6.  Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson
Journal:  Stroke       Date:  2014-10-28       Impact factor: 7.914

Review 7.  Safety of statins: an update.

Authors:  Miao Hu; Bernard M Y Cheung; Brian Tomlinson
Journal:  Ther Adv Drug Saf       Date:  2012-06

Review 8.  A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Authors:  Venkata M Alla; Vrinda Agrawal; Andrew DeNazareth; Syed Mohiuddin; Sudha Ravilla; Marc Rendell
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 9.  Etiologies of intracerebral hematomas.

Authors:  Qingliang T Wang; Stanley Tuhrim
Journal:  Curr Atheroscler Rep       Date:  2012-08       Impact factor: 5.113

Review 10.  Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.

Authors:  Daniel T Lackland; Edward J Roccella; Anne F Deutsch; Myriam Fornage; Mary G George; George Howard; Brett M Kissela; Steven J Kittner; Judith H Lichtman; Lynda D Lisabeth; Lee H Schwamm; Eric E Smith; Amytis Towfighi
Journal:  Stroke       Date:  2013-12-05       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.